

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

Claims 1-33 (canceled).

34. (original): An aqueous pharmaceutical adenovirus composition comprising a polyol in an amount effective to promote the maintenance of adenoviral infectivity.
35. (original): The composition of claim 34, further defined as maintaining an infectivity of about 70% PFU/mL to about 99.9% PFU/mL of the starting infectivity when stored for six months at 4 centigrade.
36. (original): The composition of claim 34, further defined as maintaining an infectivity of about 80% to 95% PFU/mL of the starting infectivity when stored for six months at 4 centigrade.
37. (original): The composition of claim 34, wherein said polyol is glycerol, propylene glycol, polyethylene glycol, sorbitol or mannitol.
38. (original): The composition of claim 34, wherein said polyol concentration is from about 5% to about 30% (w/v).
39. (original): The composition of claim 38, wherein said polyol concentration is from about 10% to about 30%.
40. (original): The composition of claim 34, wherein said polyol is glycerol, included in a concentration of from about 10% to about 30% (w/v).

41. (original): The composition of claim 34, wherein said composition further comprises an excipient in addition to said polyol, wherein said excipient is inositol, lactitol, xylitol, isomaltol, gelatin, agar, pectin, casein, dried skim milk, dried whole milk, silicate, carboxypolymethylene, hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methhylcellulose, methylcellulose, sucrose, dextrose, lactose, trehalose, glucose, maltose, niacinamide, creatinine, monosodium glutamate dimethyl sulfoxide, sweet whey solids, human serum albumin, bovine serum albumin, PEG, glycine, arginine, proline, lysine, alanine, polyvinyl pyrrolidine, polyvinyl alcohol, polydextran, maltodextrins, hydroxypropyl-beta-cyclodextrin, partially hydrolysed starches, Tween-20 or Tween-80.
42. (original): The composition of claim 41, wherein said composition further comprises at least a first and second of said excipients, said second excipient different from said first excipient.

Claims 43-59 (canceled).

60. (original): A method for the preparation of a long-term storage, stable adenovirus liquid formulation, comprising the steps of providing adenovirus and combining said adenovirus with a solution comprising a buffer and a polyol, whereby said adenovirus liquid formulation retains high infectivity.
61. (new): The composition of claim 34, wherein the polyol is polyethylene glycol.
62. (new): The composition of claim 34, further comprising a non-ionic detergent.
63. (new): The composition of claim 62, wherein the non-ionic detergent is Tween-20 or Tween-80.
64. (new): The composition of claim 63, wherein the non-ionic detergent is Tween-80.

65. (new): The composition of claim 34, wherein the polyol is polyethylene glycol and wherein the composition further comprises Tween-80.
66. (new): The composition of claim 34, further comprising a buffer.
67. (new): The composition of claim 66, wherein the buffer is Tris-HCl, TES, HEPES, mono-Tris, brucine tetrahydrate, EPPS, tricine, or histidine.
68. (new): The composition of claim 67, wherein the buffer is Tris-HCl.
69. (new): The composition of claim 68, wherein said Tris-HCl is included in a concentration of from about 1 mM to about 50 mM.
70. (new): The composition of claim 69, wherein said Tris-HCl is included in a concentration of from about 5 mM to about 20 mM.
71. (new): The composition of claim 66, wherein the buffer is present in the composition at a concentration at about 1 mM to 50 mM.
72. (new): The composition of claim 34, further comprising a salt selected from the group consisting of  $\text{MgCl}_2$ ,  $\text{MnCl}_2$ ,  $\text{Ca Cl}_2$ ,  $\text{ZnCl}_2$ ,  $\text{NaCl}$  and  $\text{KCl}$ .
73. (new): The method of claim 60, further defined as maintaining an infectivity of about 70% PFU/mL to about 99.9% PFU/mL of the starting infectivity when stored for six months at 4 centigrade.
74. (new): The method of claim 60, further defined as maintaining an infectivity of about 80% to 95% PFU/mL of the starting infectivity when stored for six months at 4 centigrade.

75. (new): The method of claim 60, wherein said polyol is glycerol, propylene glycol, polyethylene glycol, sorbitol or mannitol.
76. (new): The method of claim 60, wherein said polyol concentration is from about 5% to about 30% (w/v).
77. (new): The method of claim 76, wherein said polyol concentration is from about 10% to about 30%.
78. (new): The method of claim 60, wherein said polyol is glycerol, included in a concentration of from about 10% to about 30% (w/v).
79. (new): The method of claim 60, wherein said composition further comprises an excipient in addition to said polyol, wherein said excipient is inositol, lactitol, xylitol, isomaltol, gelatin, agar, pectin, casein, dried skim milk, dried whole milk, silicate, carboxypolymethylene, hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methhylcellulose, methylcellulose, sucrose, dextrose, lactose, trehalose, glucose, maltose, niacinamide, creatinine, monosodium glutamate dimethyl sulfoxide, sweet whey solids, human serum albumin, bovine serum albumin, PEG, glycine, arginine, proline, lysine, alanine, polyvinyl pyrrolidine, polyvinyl alcohol, polydextran, maltodextrins, hydroxypropyl-beta-cyclodextrin, partially hydrolysed starches, Tween-20 or Tween-80.
80. (new): The method of claim 79, wherein said composition further comprises at least a first and second of said excipients, said second excipient different from said first excipient.
81. (new): The method of claim 60, wherein the polyol is polyethylene glycol.
82. (new): The method of claim 60, further comprising a non-ionic detergent.

83. (new): The method of claim 82, wherein the non-ionic detergent is Tween-20 or Tween-80.
84. (new): The method of claim 83, wherein the non-ionic detergent is Tween-80.
85. (new): The method of claim 60, wherein the polyol is polyethylene glycol and wherein the composition further comprises Tween-80.
86. (new): The method of claim 60, wherein the buffer is Tris-HCl, TES, HEPES, mono-Tris, brucine tetrahydrate, EPPS, tricine, or histidine.
87. (new): The method of claim 86, wherein the buffer is Tris-HCl.
88. (new): The method of claim 87, wherein said Tris-HCl is included in a concentration of from about 1 mM to about 50 mM.
89. (new): The method of claim 88, wherein said Tris-HCl is included in a concentration of from about 5 mM to about 20 mM.
90. (new): The method of claim 60, wherein the buffer is present in the composition at a concentration at about 1 mM to 50 mM.
91. (new): The method of claim 60, further comprising a salt selected from the group consisting of  $\text{MgCl}_2$ ,  $\text{MnCl}_2$ ,  $\text{CaCl}_2$ ,  $\text{ZnCl}_2$ ,  $\text{NaCl}$  and  $\text{KCl}$ .